Prospective Validation of the MASA Score for Detection of Previously Unknown Atrial Fibrillation (MASA-AF)
MASA (Metabolic-Atrial-Septal-Assessment) Score for Selecting Patients for Extended ECG Monitoring: A Prospective, Blinded, Single-Center Diagnostic Accuracy Cohort Study
The MASA (Metabolic-Atrial-Septal-Assessment) score is a simple 0-8 point score built from five routinely available variables: estimated glomerular filtration rate, serum triglycerides, absence of atrial septal aneurysm, left atrial diameter, and TAPSE. In a retrospective development cohort (n=246), a score of 5 or more identified patients with atrial fibrillation (AF). This prospective study will test, in consecutive patients with cardiovascular disease or stroke without known AF admitted to the Intensive Care Unit, whether a MASA score of 5 or more identifies those in whom AF is detected by continuous ECG monitoring. The score, its threshold, and the primary outcome are fixed before enrollment and will not be changed.
研究概览
详细说明
Background: Undetected paroxysmal atrial fibrillation (AF) is a major preventable cause of stroke. Extended ECG monitoring is effective but resource-intensive; a simple score could help select patients who need it most.
Study phases: The study was approved by the Ethics Committee of the Special Hospital for Cerebrovascular Diseases "Sveti Sava" (No. 03/4310, 30 October 2026) under the title "Development of the MASA score for assessing the probability of atrial fibrillation in a retrospective cohort of cardiology patients and its prospective validation in the intensive care unit: a single-center study." Phase 1 (retrospective score development, n=246) is completed. This registration covers Phase 2, the prospective validation in consecutive patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke, or transient ischemic attack) admitted to the Intensive Care Unit.
Pre-specified score (locked before enrollment): eGFR <60 mL/min/1.73 m² (CKD-EPI 2021) = 1 point; triglycerides <=1.2 mmol/L = 1 point; atrial septal aneurysm ABSENT on echocardiography = 3 points; left atrial diameter >=46 mm = 1 point; TAPSE <=17 mm = 2 points. Score range 0-8. Positive screen = score >=5.
Procedures: Consecutive eligible patients undergo blood sampling (serum creatinine, triglycerides) and transthoracic echocardiography (left atrial diameter, TAPSE, interatrial septum assessment) shortly after ICU admission, with heart rhythm recorded at the time of echocardiography. The MASA score is calculated by an investigator not involved in rhythm assessment. All patients, regardless of score, undergo continuous ECG monitoring during the ICU stay. ECG recordings are assessed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader. AF is defined as an episode of at least 30 seconds.
Sample size: At least 61 patients with confirmed AF are required for a precise estimate of sensitivity (target 100). Enrollment continues until at least 61 (target 100) patients with confirmed AF have been enrolled; the anticipated total enrollment is approximately 700 patients, assuming a 10% AF detection rate.
Analysis: Primary-sensitivity and specificity of MASA >=5 with 95% confidence intervals. Secondary-positive and negative predictive values, area under the ROC curve, comparison with age and CHA2DS2-VASc (DeLong test), decision curve analysis, and number of patients monitored per detected AF. Pre-specified sensitivity analysis: serum creatinine >=90 umol/L instead of eGFR. Reporting will follow STARD 2015 and TRIPOD+AI 2024.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Dejan Munjiza, MD, MSc
- 电话号码:+381608018437
- 邮箱:munjizad@gmail.com
学习地点
-
-
-
Belgrade、塞尔维亚、11000
- Special Hospital for Cerebrovascular Diseases "Sveti Sava"
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Consecutive adult patients with cardiovascular disease or stroke, without previously documented atrial fibrillation, admitted to the Intensive Care Unit of the Special Hospital for Cerebrovascular Diseases "Sveti Sava", Belgrade, Serbia.
描述
Inclusion Criteria:
- Age 18 years or older
- Consecutive admission to the Intensive Care Unit with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke or transient ischemic attack)
- Sinus rhythm on the admission 12-lead ECG
- Transthoracic echocardiography and blood tests (serum creatinine, triglycerides) feasible shortly after admission
Exclusion Criteria:
- Any previously documented atrial fibrillation or atrial flutter
- Atrial fibrillation or atrial flutter on the admission ECG
- Permanent pacemaker or implantable cardioverter-defibrillator
- Mechanical mitral valve prosthesis or moderate-to-severe mitral stenosis
- Inadequate echocardiographic window for measurement of left atrial diameter, TAPSE or assessment of the interatrial septum
- Expected duration of continuous ECG monitoring shorter than 24 hours
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
ICU patients with cardiovascular disease or stroke without known AF
Consecutive adult patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke or transient ischemic attack), without previously documented atrial fibrillation, admitted to the Intensive Care Unit. All participants have the MASA score calculated and undergo continuous ECG monitoring during the ICU stay. |
Calculation of the MASA score (range 0-8) from routinely collected data: eGFR <60 mL/min/1.73 m2 = 1 point; triglycerides <=1.2 mmol/L = 1 point; atrial septal aneurysm absent on echocardiography = 3 points; left atrial diameter >=46 mm = 1 point; TAPSE <=17 mm = 2 points. A score >=5 is considered a positive screen. The score does not influence patient management; all patients undergo continuous ECG monitoring regardless of score. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sensitivity and Specificity of MASA Score >=5 for Detection of Atrial Fibrillation
大体时间:From ICU admission to ICU discharge (up to 30 days)
|
Sensitivity and specificity (with 95% confidence intervals) of a MASA score >=5 for atrial fibrillation detected by continuous ECG monitoring. Atrial fibrillation is defined as an episode lasting at least 30 seconds, confirmed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader. |
From ICU admission to ICU discharge (up to 30 days)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Positive and Negative Predictive Values of MASA Score >=5
大体时间:From ICU admission to ICU discharge (up to 30 days)
|
Positive and negative predictive values (with 95% confidence intervals) of a MASA score >=5 for atrial fibrillation detected by continuous ECG monitoring. |
From ICU admission to ICU discharge (up to 30 days)
|
|
Discriminative Performance of the MASA Score
大体时间:From ICU admission to ICU discharge (up to 30 days)
|
Area under the ROC curve (with 95% confidence interval) of the MASA score for atrial fibrillation, compared with age and CHA2DS2-VASc score using the DeLong test. |
From ICU admission to ICU discharge (up to 30 days)
|
|
Clinical Net Benefit of MASA-Guided Monitoring
大体时间:From ICU admission to ICU discharge (up to 30 days)
|
Net benefit of selecting patients for extended ECG monitoring by MASA score >=5, assessed by decision curve analysis. |
From ICU admission to ICU discharge (up to 30 days)
|
|
Number of Patients Monitored per Detected Atrial Fibrillation
大体时间:From ICU admission to ICU discharge (up to 30 days)
|
Number of patients who would need extended ECG monitoring to detect one case of atrial fibrillation when monitoring is restricted to patients with MASA score >=5. |
From ICU admission to ICU discharge (up to 30 days)
|
合作者和调查者
调查人员
- 首席研究员:Dejan Munjiza, MD, MSc、Special Hospital for Cerebrovascular Diseases "Sveti Sava"
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- MASA-AF-2026
- 03/4310 (其他标识符:Ethics Committee, SB Sveti Sava, Belgrade)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
De-identified individual participant data underlying the published results, together with the analysis code, will be made available.
IPD 共享时间框架
After publication of the primary results, for at least 5 years.
IPD 共享访问标准
Available to qualified researchers on reasonable request to the principal investigator, for non-commercial research purposes.
IPD 共享支持信息类型
- 研究方案
- 树液
- 分析代码
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.